Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Fluticasone Furoate and Batefenterol in Healthy Subjects
NCT02666287Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of batefenterol in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by GSK. Primary endpoints: Area under the plasma concentration-time curve of Fluticasone Furoate at Day 7 and Maximum observed plasma concentration of Fluticasone Furoate at Day 7. Started Jan 2016; status: completed.
02
Drugs
batefenterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02666287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02666287.